Company intelligence / Profile preview
Madison Vaccines, Inc.
- Ownership
- Private
- Development stage
- Phase 2
Overview
Madison Vaccines has developed plasmid DNA-based immunotherapies targeting prostate cancer. Their lead candidates have demonstrated safety and immune activation in clinical trials. The company focuses on combination regimens with standard-of-care therapies and checkpoint inhibitors to delay disease progression, particularly bone metastases, while maintaining quality of life. Early human data show promising immune responses and potential clinical benefit in delaying progression to overt metastases or castration therapy initiation.
- Therapeutic areas
- Oncology
- Modalities
- DNA vaccinesTherapeutic vaccinesCombination immunotherapiesMonoclonal antibodies
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Madison Vaccines, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Madison Vaccines, Inc..